Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249795 | 0.98 | L3MBTL1 (0.86) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL5251337 | 0.98 | L3MBTL1 (0.86) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL5251954 | 0.96 | L3MBTL1 (0.77) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL10355428 | 0.91 | ATM (0.81) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL4580893 | 0.91 | ATM (0.81) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL5304087 | 0.84 | MAPT (0.87) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL5915296 | 0.84 | KMT2A (0.66) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL1020053 | 0.83 | USP2 (0.76) | L3MBTL1USP2KMT2AMAPTALDH1A1 | |
| SCHEMBL4673315 | 0.82 | KMT2A (0.64) | L3MBTL1USP2KMT2AATMMAPT | |
| SCHEMBL5306092 | 0.82 | MAPT (0.69) | L3MBTL1KMT2AATMMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387949-A1 | NEW SELECTIVE MODULATORS OF INSECT NICOTINIC ACETYLCHOLINE RECEPTORS | UNIV NANTES (FR) | 2021-12-16 | — | — | US | disclosed |
| US-20210387949-A1 | NEW SELECTIVE MODULATORS OF INSECT NICOTINIC ACETYLCHOLINE RECEPTORS | UNIV NANTES (FR) | 2021-12-16 | — | — | US | disclosed |
| EP-3877377-A1 | NEW SELECTIVE MODULATORS OF INSECT NICOTINIC ACETYLCHOLINE RECEPTORS | Universite de Nantes (FR) | 2021-09-15 | — | — | EP | disclosed |
| EP-3650447-A1 | NEW SELECTIVE MODULATORS OF INSECT NICOTINIC ACETYLCHOLINE RECEPTORS | Universite de Nantes (FR) | 2020-05-13 | — | — | EP | disclosed |
| EP-3650447-A1 | NEW SELECTIVE MODULATORS OF INSECT NICOTINIC ACETYLCHOLINE RECEPTORS | Universite de Nantes (FR) | 2020-05-13 | — | — | EP | disclosed |
| US-9211279-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-03 | — | — | US | disclosed |
| US-9000029-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-26 | — | — | US | disclosed |
| US-8895606-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2608787-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-13 | — | — | US | disclosed |
| WO-2012025877-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-03-01 | — | — | WO | disclosed |
| WO-2009070497-A1 | SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | L3MBTL1 4649/4885USP2 2280/4885KMT2A 1656/4885 |
| US-20210387949-A1 | NEW SELECTIVE MODULATORS OF INSECT NICOTINIC ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA3, CHRNB3 | L3MBTL1 1806/4885USP2 3149/4885KMT2A 2883/4885 |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | L3MBTL1 4649/4885USP2 2280/4885KMT2A 1656/4885 |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | L3MBTL1 4602/4885USP2 2195/4885KMT2A 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.